- Verona Pharma said the European Patent Office had recently granted an additional key patent relating to its lead respiratory disease development candidate, ensifentrine.

The patent provided intellectual property protection throughout Europe out to 2035 for a suspension formulation of ensifentrine (suitable for nebulized administration.

A corresponding patent had already been issued in the US.

Ensifentrine was currently in a Phase 2b clinical trials for chronic obstructive pulmonary disease.

The first-in-class inhaled therapy had both bronchodilator and anti-inflammatory activity in a single agent and had the potential to address a major unmet need in COPD, the company said.

At 2:16pm: [LON:VRP] Verona Pharma PLC share price was 0p at 60p

Story provided by